India, known as the 'pharmacy of the world' for its extensive production of affordable generic medicines, is seeking bilateral discussions with the United States to address President Donald Trump's proposal to impose at least a 25% tariff on pharmaceutical imports. In fiscal year 2024, India's pharmaceutical exports to the U.S. amounted to $8.7 billion, representing approximately 31% of its total pharma exports. The Indian Pharmaceutical Alliance (IPA), representing major drugmakers, expressed confidence that ongoing dialogue would help resolve the issue. Industry experts warn that such tariffs could lead to increased costs for American consumers, as Indian generics have historically provided significant savings to the U.S. healthcare system. The situation remains fluid, with both nations expected to engage in discussions to find a mutually beneficial resolution.